FDA QMSR Inspections: Is Your Quality System Ready?

For years, FDA inspections felt like a known variable. Teams prepared in familiar ways and treated FDA inspection readiness as a project that ramped up ahead of an expected visit.

That stability is fading as the shift from QSIT to QMSR (Quality Management System Regulation) signals a different view of the medical device quality system, and it changes what inspectors prioritize once they are onsite.  Many leaders know QMSR aligns more closely with ISO 13485, although fewer have fully internalized what the new inspection logic demands, especially as one-day inspectional assessments expand the FDA’s reach in 2026. 

This article draws on practitioner perspectives from Akkodis regulatory compliance experts Brian Nelson and Mike Silvola, shaped for life sciences leaders seeking clarity on what’s changing in the inspection room and what separates confident organizations from exposed ones.

From QSIT to QMSR Changes the Core Question in FDA Inspections 

QSIT created a structure that many medical device manufacturers learned to anticipate. Inspections often felt like a guided review of subsystems, with heavy emphasis on procedures, records, and whether evidence matched the documented process.

With QMSR and ISO 13485 alignment, inspectors increasingly evaluate whether risk-based thinking organizes the full quality system, not only design documentation. The questions move beyond whether procedures exist and toward whether risk is identified, controlled, and monitored in ways that stay effective over time.

In practice, inspection conversations are now more likely to probe how signals connect across the QMS. When risk management, CAPA, complaints, and design controls operate as separate tracks, gaps are created.  When those elements are connected and decision-making is consistent, the QMS is more robust, and the organization can explain its system with confidence rather than relying on individuals to translate the story.

Risk-Based Thinking Has to Show Up Across the Whole Medical Device Quality System

Many organizations have risk assessments that were completed thoughtfully, but static risk documents do not carry the same protective value as an active risk management system. A risk-based medical device quality system must treat risk using continual active inputs that shape prioritization, investigation depth, control selection, and leadership oversight.

That expectation also changes how the FDA interprets compliance.  QMS elements such as CAPA, complaints, supplier quality, and design controls cannot behave like siloed programs that only connect during an escalation. Under QMSR, the ability to show how signals move across the system often becomes the difference between a clean inspection narrative and a fragmented one.

Internal audits and management review can also work in a company’s favor when they are run as genuine feedback loops. When an organization can show it identifies gaps, understands risk implications, and is working the plan, inspection discussions will become much easier.

One-Day Inspectional Assessments Raise the Stakes for FDA Inspection Readiness

The inspection framework is changing, and inspection activity is changing alongside it. The FDA’s one-day inspectional assessment pilot increases surveillance coverage through shorter, targeted visits that can broaden quickly when issues surface.

The operational implication is simple. More facilities may see an inspector, including sites that have not been inspected in years, and selection can be driven by risk indicators that include time since the last inspection.

Mike Silvola captures the point leaders need to align on, saying, “Whether you’re getting a one-day inspection or a full inspection, the bottom line is the same. Your systems must be continuously inspection-ready.”

That mindset adjustment matters because inspection readiness is moving away from event preparation and toward steady-state control.

What FDA Inspection Trends Are Signaling Through 483s and Warning Letters

A new inspection framework and a new inspection cadence are only part of the story. The other part is what inspectors continue to cite when they find weaknesses, because those patterns reveal how the FDA is interpreting quality system effectiveness in practice.

In their work with teams responding to inspections, Brian Nelson and Mike Silvola have seen consistent themes over the past 18 months that point to systemic issues, not isolated mistakes. The details vary by site, but a few areas tend to separate well-run systems from brittle ones.

CAPA Effectiveness Often Fails Where Systems Get Treated as Paperwork

Organizations have CAPA procedures and can show CAPA records. The difference shows up in timeliness, true root cause investigations, and whether effectiveness checks are meaningful. When CAPA becomes a documentation exercise, recurring issues will follow, and those recurrences are difficult to defend during an inspection conversation.

Data Integrity Is a Growing Pressure Point in Digital Quality Environments

Data integrity continues to appear as a theme in inspection outcomes, and it becomes even more sensitive as AI tools enter regulated workflows without clear governance. When teams cannot explain how data is created, changed, reviewed, and protected, the credibility of the system erodes quickly.

Complaint Handling and Supplier Quality Often Reveal the Real Health of the System

Complaint handling and supplier quality issues are potential warning signals because they sit at the intersection of product performance, risk assessment, investigation discipline, and change control. When these areas are weak, they can point to broader gaps in how risk is identified and managed across the medical device quality system.

Process Validation and Procedure Adherence Still Matter Because They Prove Control 

Even as the model shifts toward risk-based thinking, foundational control still matters. Procedure adherence and process validation remain key because they show whether the organization can execute consistently, and whether variability is understood and managed.

Across these themes, the through-line is consistent. The FDA is not only looking for fixes. Inspectors are increasingly evaluating how decisions were made, whether leadership understands the risk, and whether the organization can explain its system without relying on legacy knowledge. 

Continuous Inspection Readiness Is Becoming a Culture Test

The organizations that navigate this new era well do not aim for perfection, but rather strive for control and transparency. 

They know where risk lives, they surface issues before an inspector does, and they can explain what they did, why they did it, and how they know it worked. That is what a defensible quality system looks like under QMSR, and that is what the one-day inspectional assessment pilot reinforces. 

Akkodis supports life sciences organizations with deep regulatory compliance expertise across FDA inspection readiness, remediation, quality system transformation, and CAPA execution, grounded in practitioners who have led work inside inspection rooms and at scale. If you’re looking for support in this area, contact our team today.

To learn more about what the new inspection era demands, look for the next article in this series, where we’ll explore how to design risk connectivity across the QMS so inspection readiness becomes part of daily operations rather than a last-minute rush.